ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR/CD3 Protease-activated T-cell Engager VIR-5525

Its studies are led by Vir Biotechnology.

Furthest: phase 1, since Apr 21, 20251 company-led study, 1 open or runningNext primary completion: Aug 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vir Biotechnology11 open or runningphase 1since Apr 21, 2025Apr 21, 2025Aug 2029phase 1 · NCT06960395

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2025First study: phase 1 study in Solid Tumor MalignanciesFirst studyNCT06960395 · 450 planned · United States, Australia

Ahead

  1. Aug 2029Primary completion: phase 1 study in Solid Tumor MalignanciesNCT06960395

TargetBeta

EGFR →read by rule
“A protease-activated, dual-masked, prodrug T-cell engager (TCE) composed of an epidermal growth factor receptor (EGFR)-binding domain and a CD3-binding domain ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06960395Solid Tumor Malignancies · United States, Australia1RecruitingAug 2029450

How it is read

Names in the registry

  • “VIR-5525”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.